chloroquine/悪性腫瘍

FIELD OF THE INVENTION The present invention relates to methods for treating cancer in a subject by administering chloroquine to a subject in need thereof. The chloroquine is administered in amounts sufficient to induce production and/or secretion of the tumor suppressor prostate apoptosis

INTRODUCTION Ductal Carcinoma In Situ (DCIS) is the most common type of malignant precursor of breast neoplasia in women [1-4]. DCIS accounts for an estimated 30% of the 185,000 breast cancers detected by mammography each year. While the majority, if not all, invasive breast carcinoma emerges from a

FIELD OF THE INVENTION The present invention is directed to the field of medicine and more specifically to the use of certain compounds for the treatment and prevention of inflammatory and cancerous conditions, especially in liver. BACKGROUND Treatment and prevention of inflammatory and cancerous

FIELD OF THE INVENTION The present invention relates to a treatment of a solid tumour, in particular a disseminated solid tumour, in a person affected by cancer and to a means for such treatment. BACKGROUND OF THE INVENTION New and effective anticancer drugs need to be developed for patients that

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a .sctn. 371 national stage entry of International Application No. PCT/EP2015/074092, filed Oct. 19, 2015, which claims priority to European Patent Application No. 14189304.0, filed Oct. 17, 2014, the entire contents of which is

FIELD OF INVENTION The field of the invention generally relates to methods and products for treating proliferative diseases, using combinations of compounds to inhibit cellular metabolism. BACKGROUND Normal tissue develops, and is maintained by, processes of cell division and cell death. In many

BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to tetrahydronaphthalene derivatives and to starting materials thereof. SUMMARY OF THE INVENTION The present invention relates to tetrahydronaphthalene derivatives, and in particular, is concerned with

BACKGROUND OF THE INVENTION The main reason for failure in the treatment of cancer patients is resistance to conventional chemotherapeutics. One type of drug resistance is referred to as multiple resistance to cytostatics (multidrug resistance); this multiple resistance is characterized by a

BACKGROUND OF THE INVENTION The main reason for failure in the treatment of cancer patients is resistance to conventional chemotherapeutics. One type of drug resistance is referred to as multiple resistance to cytostatics (multidrug resistance); this multiple resistance is characterized by a